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ABSTRACT
Objective: To describe the clinical impact of the first year 
treatment with dornase alfa, according to age groups, in a 
cohort of Brazilian Cystic Fibrosis (CF) patients. 
Methods: The data on 152 eligible patients, from 16 CF 
reference centers, that answered the medical questionnaires 
and performed laboratory tests at baseline (T0), and at six 
(T2) and 12 (T4) months after dornase alfa initiation, were 
analyzed. Three age groups were assessed: six to 11, 12 to 
13, and ≥14 years. Pulmonary tests, airway microbiology, 
emergency room visits, hospitalizations, emergency and rou-
tine treatments were evaluated. Student’s t-test, chi-square 
test and analysis of variance were used when appropriated. 
Results: Routine treatments were based on respiratory 
physical therapy, regular exercises, pancreatic enzymes, 
vitamins, bronchodilators, corticosteroids, and antibiotics. 
In the six months prior the study (T0 phase), hospitaliza-
tions for pulmonary exacerbations occurred in 38.0, 10.0 and 
61.4% in the three age groups, respectively. After one year of 
intervention, there was a significant reduction in the number 
of emergency room visits in the six to 11 years group. There 
were no significant changes in forced expiratory volume in 
one second (VEF
1
), in forced vital capacity (FVC), in oxygen 
saturation (SpO
2
), and in Tiffenau index for all age groups. 
A significant improvement in Shwachman-Kulczychi score 
was observed in the older group. In the last six months of 
therapy, chronic or intermittent colonization by P. aeruginosa 
was detected in 75.0, 71.4 and 62.5% of the studied groups, 
respectively, while S. aureus colonization was identified in 
68.6, 66.6 and 41.9% of the cases. 
Conclusions: The treatment with dornase alfa promoted 
the maintenance of pulmonary function parameters and was 
associated with a significant reduction of emergency room 
visits due to pulmonary  exacerbations in the six to 11 years 
age group, with better clinical scores in the ≥14 age group, 
one year after the intervention.
Key-words: cystic fibrosis; dornase alfa; therapeutics; 
clinical evolution; pulmonary microbiology. 
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RESUMO
Objetivo: Relatar o impacto clínico do primeiro ano de 
tratamento com dornase alfa de acordo com a faixa etária, 
numa coorte de pacientes brasileiros com fibrose cística (FC). 
Métodos: O presente estudo analisou dados de 152 pacientes 
elegíveis, de 16 centros de referência para FC, os quais responde-
ram aos questionários clínicos e realizaram testes laboratoriais, 
ao início do tratamento com dornase alfa (T0) e após seis (T2) e 
12 (T4) meses da intervenção. Analisaram-se três grupos etários: 
seis a 11, 12 a 13 e ≥14 anos de idade. Avaliaram-se os testes 
pulmonares, a microbiologia de vias aéreas, os atendimentos de 
emergência, as hospitalizações e os tratamentos emergenciais e 
rotineiros. O teste t de Student, o qui-quadrado e a análise de 
variância foram usados quando pertinentes.  
Resultados: O tratamento baseou-se em fisioterapia respi-
ratória, exercícios regulares, enzimas pancreáticas, vitaminas, 
broncodilatadores, corticosteroides e antibióticos. Nos seis 
meses anteriores ao estudo (fase T0), as hospitalizações por 
exacerbação pulmonar ocorreram em 38,0, 10,0 e 61,4%, 
respectivamente para as três faixas etárias analisadas. No grupo 
de seis a 11 anos, houve redução significativa de atendimentos 
de emergência após um ano de tratamento. Não houve modifi-
cações significativas de volume expiratório forçado no primeiro 
segundo (VEF
1
), capacidade vital forçada (CVF), saturação de 
oxigênio (SpO)
2 
e índice de Tiffeneau em todos os grupos. O 
escore de Shwachman-Kulczychi melhorou significativamente 
no grupo de mais idade. Nos últimos seis meses de tratamen-
to, a colonização crônica ou intermitente por P.aeruginosa foi 
detectada em 75,0, 71,4 e 62,5%, respectivamente, enquanto 
a colonização por S.aureus ocorreu em 68,6, 66,6 e 41,9% dos 
casos em cada grupo etário. 
Conclusões: A intervenção com dornase alfa resultou 
em manutenção dos parâmetros pulmonares e associou-se à 
redução significativa de visitas à emergência por exacerbação 
pulmonar no grupo de seis a 11 anos de idade, com melhora 
do escore clínico no grupo ≥14 anos de idade ao final de um 
ano de estudo.   
Palavras-chave: fibrose cística; dornase alfa; terapêutica; 
evolução clínica; microbiologia pulmonar.                       
RESUMEN
Objetivo: Relatar el impacto clínico del primer año de 
tratamiento con dornasa alfa conforme a la franja de edad, en 
una cohorte de pacientes brasileños con fibrosis quística (FC). 
Métodos: El presente estudio analizó datos de 152 pa-
cientes elegibles, de 16 centros de referencia para FC, los que 
contestaron a los cuestionarios clínicos y realizaron pruebas 
laboratoriales, al inicio del tratamiento con la dornasa alfa 
(T0) y después de 6 (T2) y 12 (T4) meses de la intervención. 
Se analizaron 3 grupos etarios: 6–11, 12–13 e >14 años de 
edad. Se evaluaron las pruebas pulmonares, la microbiología 
de vías aéreas, las atenciones de emergencia, hospitalizaciones 
y tratamientos emergenciales y de rutina. Las estadísticas 
descriptivas, pruebas t y chi-cuadrado y ANOVA fueron 
usadas cuando pertinentes.  
Resultados: El tratamiento regular se basó en la fisiote-
rapia respiratoria, ejercicios regulares, encimas pancreáticas, 
vitaminas, broncodilatadores, corticosteroides y antibióticos. 
En los 6 meses anteriores al estudio (fase T0), las hospitali-
zaciones por exacerbación pulmonar ocurrieron en 38, 10 y 
61,4%, respectivamente, para las tres franjas de edad analiza-
das. En el grupo 6–11 años, hubo reducción significativa de 
atenciones de emergencia después de 1 año de tratamiento. 
No hubo modificaciones significativas de volumen espirato-
rio forzado en el 1er segundo (VEF
1
), capacidad vital forzada 
(CVF), saturación de oxígeno (SpO)
2
 e índice de Tiffeneau, en 
todos grupos. El escore de Schwachman-Kulczychi mejoró 
significativamente en el grupo de más edad. Los últimos 6 
meses de tratamiento, la colonización crónica o intermitente 
por P. aeruginosa fue detectada en el 75, 71,4 y 62,5%, res-
pectivamente, mientras que por S. aureus ocurrió en 68,6, 
66,6 y 41,9% de los casos en cada grupo de edad.
Conclusiones: La intervención con dornasa alfa resultó 
en mantenimiento de los parámetros pulmonares y fue aso-
ciada a la reducción significativa de visitas a la emergencia 
por exacerbación pulmonar en el grupo de 6 a 11 años de 
edad, con mejora del escore clínico en el grupo ≥14 años 
de edad, al final de un año de estudio.   
Palabras clave: fibrosis quística; dornasa alfa; tratamiento; 
evolución clínica; microbiología pulmonar.
Introduction
Cystic fibrosis (CF) is the most common life-threatening 
autosomal recessive disorder among Caucasians(1,2). Caused by 
a mutation in the cystic fibrosis transmembrane conductance regu-
lator (CFTR) gene, this disease is characterized by progressive 
lung destruction, with accumulation of viscous secretions 
and impairment of mucociliary clearance in airways(3,4) 
Chronic pulmonary infection and increased inflammatory 
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response are hallmarks of CF lung disease,  with a major 
impact on patients’ morbidity and the mortality(4-6). 
Long-term accumulation of thickened mucus leads to 
chronic suppurative lung disease, with persistent infection 
or colonization by microorganisms such as Pseudomonas 
aeruginosa, Staphylococcus aureus, and Burkholderia cepacia, 
and evolution to bronchiectasis, pneumothorax, cor pulmo-
nale, and respiratory failure, at the final stage of disease(7). 
Gastrointestinal and reproductive systems are also affected 
with pancreatic insufficiency with maldigestion and mal-
absorption of nutrients, distal intestinal obstruction, and 
hepatic disease. In addition, salt loss syndromes, diabetes 
mellitus, and genitourinary abnormalities are other clinical 
complications of CF(2,8).
Improvements in CF diagnosis and treatment strategies 
led to an increase in life expectancy, raising the median age 
of survival to 36 years in the United States1  and around 
18  years in Brazil(9). Although no cure exists, several thera-
peutic strategies are available for clinical use and current 
standard treatments for CF include antibiotics, respiratory 
physical therapy and mucolytic agents (dornase alfa, hyper-
tonic saline solutions), bronchodilators, pancreatic enzymes, 
and daily supplementation with vitamins(5,8,10).   
Clinical use of dornase alfa, a recombinant human deoxyri-
bonuclease I that  reduces the viscosity of CF sputum through 
the hydrolization of DNA accumulated in secretions(11), has 
demonstrated significant efficacy in CF, as it reduces respira-
tory exacerbations and improves lung function, regardless 
of patients age or disease stage(5,12,13).  
Health-related quality of life (HRQoL) has gained im-
portance lately as an endpoint for clinical trials, so we have 
conducted a multicenter prospective study to investigate 
the impact of dornase alfa introduction on patients’ QoL. In 
our previous publication(14) we used modified, Portuguese-
translated, validated CF QoL questionnaires CFQ-R (Cystic 
Fibrosis Questionnaire-Revised)(15), with dornase alfa pro-
moting significant improvements in various CFQ-R do-
mains. The aim of this publication is to present additional 
information about the clinical profile of CF Brazilian patients 
after starting dornase alfa chronic use and to analyze their 
clinical parameters and patterns of care.
Method
This paper shows complementary data of the 152 CF pa-
tients from the Brazilian Cystic Fibrosis Quality of Life Trial(14). 
Study design, simple size, patient eligibility criteria, and part 
of patients’ demographic and clinical characteristics have been 
described previously(14). Free informed consent form was signed 
by patients or their guardians and this project was approved by 
human research ethics committees of all Centers(14).
Patients were followed in five outpatient visits: previous 
to dornase alfa initiation (T0), and then every 3 months 
until one year of follow up — 3 (T1), 6 (T2), 9 (T3) and 
12 (T4) months, respectively.  In all visits, disease-specific 
questionnaires, CFQ-R translated and validated, were used 
in patients aged from 6 to 11, 12 to 13 and 14 years or more, 
and in parents of patients aged 6 to 13 years(15,16). The re-
sponsible physician evaluated patient’s medical record forms 
covering the last six months, prior to study entry (T0), and 
at 6 months (T2) and 12 months (T4) of dornase alfa. For 
each patient, these three forms and the following parameters 
were collected:  method of CF diagnosis; reason, number and 
duration of hospitalizations; reason and number of visits to 
the emergency room; concomitant interventions routinely 
used; pulmonary function parameters forced expiratory 
volume in 1 second (FEV
1
, forced vital capacity [FVC], oxy-
gen saturation of hemoglobin [SpO
2
] and Tiffeneau index); 
Shwachman-Kulczychi score; treatments for pulmonary 
exacerbations; use of antibiotics and airways microbiology. 
Patient condition/evolution and reason for follow-up inter-
ruption were obtained after 6 and 12 months. In addition, 
a clinical stability questionnaire was used to evaluate the 
clinical conditions in the previous month(14).
Genetic studies were performed by specific polymerase 
chain reaction. At each visit, physical examination, labora-
tory measures, and a spirometry were performed. Sputum 
cultures were collected routinely and considered positive when 
the following microorganisms were presented in at least one 
sample: S. aureus; P. aeruginosa; B. cepacia or Stenotrophomonas 
maltophilia. The colonization was defined as chronic when 3 
positive samples were obtained, in previous 6 months.
The following variables were analyzed: age, gender, 
symptoms, diagnosis, medication use, pulmonary function 
parameters, concomitant treatments, and airway microbiol-
ogy. Clinical outcomes and data on concomitant treatments, 
medication use, and routine therapies were based on data 
recorded.
Patients were analyzed according to the age-groups(14,16). 
Data were summarized using descriptive statistics suitable 
for each variable. Frequency and percentages were used for 
categorical variables and for ordinal numerical variables. 
Number of valid observations, range, mean, standard de-
viation (SD), median, and interquartile range were used to 
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describe continuous numerical variables, including FEV
1
, 
FVC, SpO
2
, Tiffeneau index, and Shwachamn-Kulczychi 
score. Values for percentage of predicted FEV
1 
and FVC were 
calculated. Parametric data were compared between two 
groups using t-test for paired samples, when appropriated. 
Comparison between three or more means was performed 
using the analysis of variance. Changes in FEV
1
, FVC, SpO
2
, 
Tiffeneau index and Shwachman-Kulczychi score were as-
sessed using the analysis of variance for repeated measures 
and multiple comparisons. The number of visits to the 
emergency room due to acute pulmonary exacerbations was 
compared over time using the McNemar test for dependent 
samples, and using Chi-square test for independent samples. 
Statistical analyses were performed using the SAS software 
(SAS Institute Inc). Two-sided p<0.05 were considered 
statistically significant. 
Sample size calculation was performed as previously 
described and based on the primary endpoint of the study 
which was the quality of life(14). Briefly, based on the vari-
ance analysis of the CFQ-R punctuation found in a previous 
study(15) it was estimated that the inclusion of 64 patients per 
age group would give the study a power of 80% to detect a 
variation of 6.5% in the Respiratory Symptoms domain of 
the Cystic Fibrosis Questionnaire-Revised (CFQ-R) based 
on a two-sided type I error ≤5%.
Results
Of the 156 initial patients, four were excluded for not meeting 
the inclusion criteria. Among the 152 eligible patients, 79 were 
in age group 6 –11, 14 were in age group 12–13, and 59 were 
in age group ≥14 years, from 16 CF referral centers. Overall and 
Table 1 - Outpatient clinic and emergency room visits, hospitalizations, and pulmonary function parameters in the last 6 months 
prior to the study entry, and at 6 and 12 months after dornase alfa initiation in patients aged 6–11 years. Part of these results was 
previously published(14)
T0 T2 T4 p-value
Visits to the emergency room 23/77 (29.9%) 9/67 (13.4%) 13/60 (21.7%) 0.060
Visits to the emergency room due to 
acute exacerbations*
13/23 (56.5%) 4/9 (44.4%) 2/13 (15.4%) 0.056
Hospitalization due to acute 
exacerbations
14/77 (18.2%) 7/67 (10.4%) 5/60 (8.3%) 0.181
Visits to outpatient clinic due to acute 
exacerbations
37/77 (48.1%) 31/67 (46.3%) 25/60 (41.7%) 0.751
FEV1(% predicted)** n=61 n=55 n=52
Mean±SD 79.5±21.1 81.3±22.0 83.4±21.7 0.411
Median (range) 79.0 (29.0–115.0) 80.0 (14.0–147.0) 84.0 (44.0–132.0)
FVC (% predicted)** n=61 n=54 n=52
Mean±SD 86.7±19.7 88.5±18.0 89.4±20.0
Median (range) 87.0 (47.0–131.0) 91.5 (49.0–135.0) 92.5 (50.0–149.0) 0.580
SpO2** n=51 n=49 n=43
Mean±SD 96.0±2.3 95.6±7.0 97.0±2.1 0.227
Median (range) 96.0 (89.0–99.0) 97.0 (58.0–100.0) 97.0 (88.0–100.0)
Tiffeneau index** n=60 n=56 n=51
Mean±SD 85.9±15.9 88.3±11.7 86.2±13.3
Median (range) 89.0 (33.0–116.6) 89.0 (43.0–110.0) 86.0 (50.0–109.5) 0.551
Shwachman-Kulczychi score** n=72 n=58 n=50
Mean±SD 80.7±12.2 83.0±11.8 83.1±12.0
Median (range) 80.0 (55.0–100.0) 85.0 (55.0–100.0) 85.0 (52.0–100.0) 0.268
*McNemar test (dependent times): T0=T2; T0=T4 e T2=T4; Fisher exact test (independent times): T0=T2; T0>T4 e T2=T4; **p-values were cal-
culated using repeated measures analysis of variance; T0: baseline visit; T2: visit at 6 months of dornase alfa; T4: visit at 12 months of dornase 
alfa; FVC: forced vital capacity; SpO2: oxygen saturation; SD: standard deviation; VEF1: forced expiratory volume in 1 second
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per age group descriptive analysis of gender, age, age at diagnosis, 
and clinical manifestations were previously described(14). During 
the follow-up, 14 patients were lost for the following reasons: 
withdrawal from the treatment (4), death (3), frequently missed 
visits (1), transference to another city/state (1), pregnancy (1), 
lack of medication at the distribution site (1), drug intolerance 
(1), low adherence (1) and adverse reaction n(1). 
The main method of CF diagnosis was based on two sweat 
tests associated or not to genetic studies. In the younger 
group, ΔF508 in homozygotic state was the most frequent 
mutation (42.9%), followed by ΔF508 in heterozygosis 
(32.1%) and unknown mutations (14.3%). In patients 
aged ≥14 years, the most common mutations were ΔF508 
in heterozygosis (31.3%), ΔF508 in homozygosis (18.8%) 
and unknown mutations (37.5%). Other mutations, E542X/
B10665, G542X/N1303K, R1162X/R1162, W1282X/N, 
and ΔF508/R553X, were detected.
Pulmonary function parameters and data related to hos-
pitalization are presented in Tables 1 to 3. 
Data on patients aged from 6 to 11 years are summarized 
in Table1. During the study, patients in this group required 
hospitalizations; most cases lasted from 11 to 20 days and 
were predominantly due to pulmonary infections. There was 
a significant reduction in the number of emergency room 
visits due to acute exacerbations when T4 was compared to 
T0. This age group showed no significant changes in FEV
1
, 
FVC, SpO
2
, Tiffeneau index and Shwachman-Kulczychi score 
after 6 and 12 months of dornase alfa. 
Regarding the age group 12–13 years, pulmonary func-
tion parameters are summarized in Table 2. Due to sample 
size limitations, no statistical comparisons were made for 
this group regarding outcomes over time. 
For the group aged ≥14 years, 16 patients were hospital-
ized due to pulmonary infections, with a length of stay that 
varied from 10 to 20 days. There were many visits to emer-
gency rooms. When time points T0–T4 were compared, no 
significant differences were observed regarding the number of 
visits due to acute exacerbations. In addition, treatment with 
dornase alfa for 6 and 12 months was not associated with sig-
nificant changes in pulmonary function parameters, with the 
exception of Shwachman-Kulczychi score that showed a sig-
nificant improvement after 6 months of dornase alfa (Table 3). 
Table 2 - Outpatient clinic and emergency room visits, hospitalizations and pulmonary function parameters in the last 6 months prior 
to study entry, at 6 and 12 months after dornase alfa initiation in patients aged 12-13 years. Part of these results was previously 
published(14)
T0 T2 T4
Visits to the emergency room 2/13 (15.4%) 4/11 (36.4%) 0/10 (0.0%)
Hospitalization due to acute 
exacerbations
1/13 (7.7%) 3/11 (27.3%) 1/10 (10.0%)
Visits to outpatient clinic due to acute 
exacerbations
3/13 (23.1%) 3/11 (27.3%) 4/10 (40.0%)
FEV1(% predicted) n=12 n=9 n=9
Mean±SD 68.6±15.2 67.4±16.1 67.0±17.2
Median (range) 69.0 (42.0–94.0) 66.0 (42.0–99.7) 61.3 (44.0–99.0)
FVC(% predicted) n=12 n=9 n=9
Mean±SD 80.7±16.4 80.1±14.8 81.7±16.9
Median (range) 75.7(52.7–114.1) 72.0(67.0–102.0) 75.0(60.0–107.3)
SpO2 n=10 n=8 n=7
Mean±SD 96.7±1.9 96.8±1.3 96.3±2.8
Median (range) 97.0 (93.0–99.0) 97.0 (95.0–98.0) 97.0 (91.0–99.0)
Tiffeneau index n=12 n=10 n=8
Mean±SD 81.2±10.9 83.5±12.5 83.8±11.5
Median (range) 82.0 (63.0–103.0) 83.0 (63.0–103.1) 87.5 (66.0–98.0)
Shwachman-Kulczychi score n=12 n=7 n=8
Mean±SD 75.2±13.3 77.4±15.5 81.1±10.9
Median (range) 75.0 (55.0–97.0) 80.0 (50.0–97.0) 84.0 (60.0–95.0)
T0: baseline visit; T2: visit at 6 months of dornase alfa; T4: visit at 12 months of dornase alfa; FVC: forced vital capacity; SpO2: oxygen saturation; 
SD: standard deviation; VEF1: forced expiratory volume in 1 second
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Analysis of airways microbiology is shown in Table 4. 
In all age groups, P. aeruginosa and S. aureus were the most 
frequent pathogens found in chronic and intermittent 
colonization. During the first six months of dornase alfa, 
chronic P. aeruginosa was detected in 37.9%, 37.5% and 
47.4% of the patients in age groups 6-11, 12-13 and ≥14 
years, respectively, while chronic S. aureus was identified in 
20.0%, 44.4% and 22.5% of the patients. When chronic 
and intermittent colonization were grouped, P. aeruginosa 
was found in more than 60% of the sample during treat-
ment with dornase alfa, while S. aureus colonization showed 
a prevalence higher than 40-60%, for all age groups. 
The routine concomitant treatments during the study 
follow-up are shown in Table 5.
The missing data has many reasons as incompletely 
fulfilled documents, patients’ faults to clinics, physician 
misunderstanding of proposed questions, and CF younger 
patients lack of cooperation during pulmonary tests.   
Discussion
We described the clinical characteristics and outcomes of 
the 152 patients included in the Brazilian Cystic Fibrosis 
Quality of Life Trial(14). The selection of CF patients in the 
16 referral centers was based on the physicians’ decision to 
initiate chronic treatment with dornase alfa, following the 
recommendations of current consensus(1,5), with no additional 
costs to the routine treatment, as this medication is regularly 
dispensed by our government. According to the interna-
tional guidelines, the chronic use of dornase alfa, aiming 
at improving lung function and reducing exacerbations in 
children with 6 years of age and older in moderate to severe 
Table 3 - Outpatient clinic and emergency room visits, hospitalizations and pulmonary function parameters in the last 6 months 
prior to the study entry, at 6 and 12 months after dornase alfa initiation in patients aged ≥14 years. Part of these results was pre-
viously published(14)
T0 T2 T4 p-value
Visits to the emergency room 20/74 (27.0%) 13/49 (26.5%) 8/38 (21.1%) 0.443
Visits to the emergency room due to 
acute exacerbations 11/19 (57.9%) 6/13 (46.2%) 7/8 (87.5%) 0.166
Hospitalization due to acute 
exacerbations* 21/59 (35.6%) 8/49 (16.3%) 5/38 (13.2%) 0.014
Visits to outpatient clinic due to acute 
exacerbations 35/59 (59.3%) 24/49 (49.0%) 1338 (34.2%) 0.054
FEV1 (% predicted) n=52 n=47 n=35
Mean±SD 65.1±22.7 64.6±23.5 67.1±22.3
Median (range) 70.4 (17.0–115.0) 68.6 (14.0–118.0) 70.0 (25.0–119.0) 0.864
FVC(% predicted) n=51 n=47 n=35
Mean±SD 74.5±21.6 75.9±22.0 77.8±21.5
Median (range) 78.0 (24.0–121.0) 78.1 (19.0–118.0) 77.0 (32.6–125.0) 0.603
SpO2 n=44 n=42 n=32
Mean±SD 95.4±3.6 95.6±2.9 95.8±2.2 0.924
Median (range) 96.0 (78.0–100.0) 96.0 (86.0–100.0) 96.0 (89.0–100.0)
Tiffeneau index n=54 n=45 n=36
Mean±SD 76.2±15.7 74.9±15.7 78.9±15.8 0.160
Median (range) 78.2 (37.0–109.0) 73.0 (42.0–101.0) 80.5 (41.6–103.0)
Shwachman-Kulczychi score** n=39 n=31 n=24
Mean±SD 75.2±15.2 79.3±12.1 79.2±12.6 0.046*
Median (range) 80.0 (45.0–100.0) 80.0 (50.0–99.0) 80.0 (50.0–95.0)
*McNemar test (dependent times) and Chi-square (independent times): T0<>T2; T0<>T4 and T2=T4; **T0<T2, T0=T4, T2=T4); T0: baseline visit; 
T2: visit at 6 months of dornase alfa; T4: visit at 12 months of dornase alfa; FVC: forced vital capacity; SpO2: oxygen saturation; SD: standard 
deviation; FEV1: forced expiratory volume in 1 second
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lung disease, is a strong recommendation, grade A, with 
good level of evidence and substantial benefit(5).  It was also 
recommended for CF patients with mild lung disease by the 
European Consensus(17). Our aim was to investigate whether 
the improvements observed in patients’ QoL(14) would also 
reflect benefits in clinical status. 
In the previous studies(14,15), CF patients were divided into 
three age groups according to the original protocol of the 
CFQ-R(16). The formal inclusion of CFQ-R questionnaires 
as a clinical outcome was essential, as it detected the impact 
of dornase alfa treatment over QoL, from the perspective of 
patients and their families. It allowed the identification 
of baseline reference values for QoL in the different age 
groups, and the progression of the QoL domains scores over 
the time (14,15,18). The present paper was an attempt to rescue 
the outcomes of distinct age groups. Thus, it would be pos-
sible to make comparisons between these groups, to evaluate 
individual patients in relation to the baseline characteristics 
of their respective age groups, and to plan future strategies.
Patients aged 6 to 11 years were those who most benefited 
from the use of dornase alfa. A significant reduction in the 
number of emergency room visits due to acute exacerbations 
was coincident with improvement in the QoL Respiratory 
Domain of previous paper(14). The significant improvement 
in the Shwachman-Kulczychi score observed in the older 
group can also be pointed as a positive outcome of the 
therapy, and when considered together with the favorable 
results in CFQ-R other domains(14), it allows the conclusion 
that dornase alfa is an additional therapeutic option for CF. 
Recently, dornase alfa was included in the recommenda-
tions of the Ministerial Order SAS/MS, n° 224, emended 
in 2010(19). Evidently the cost-benefit relationship of this 
therapeutics was carefully revised by ANVISA (National 
Agency of Sanitary Surveillance) before its implementation 
in routine usage(19).
 Regarding patients’ characteristics, mean age at diagnosis 
was 9.3 years, ranging from <1 to 56 years, and the main 
clinical manifestations were pulmonary infections, malnu-
trition and pancreatic insufficiency, as in other studies. The 
CF diagnosis occurred late in all age groups (median age at 
diagnosis, 4.0 and 15.0 years); as already known, the late 
diagnosis results in worse prognosis of CF lung disease. 
Fortunately, improvements in age at diagnosis has been 
observed in recent Brazilian research(20).
In our study, ΔF508 was the most frequent mutation 
detected in agreement with genotype distribution study of 
Brazilian patients from five different states (overall frequency 
of 48%)(20,21). According to the Cystic Fibrosis Foundation’s 
Patient Report 2009, almost 91% of the CF patients have 
their mutations identified, and the ΔF508 mutation is pres-
ent in near 90% of cases(1). Mutations found in our study 
are among the most common mutations detected in CF(1,20).
Persistent airway colonization has a devastating impact 
on patient’s life spam and contributes to local inflammatory 
response and to progressive deterioration of lung function 
with age(2) P. aeruginosa and S. aureus are of primary impor-
tance in chronic infections. Gangell et al. suggested that 
pulmonary inflammatory response may vary according to 
the infecting organism, and P. aeruginosa was associated with 
greater levels of inflammation(22). S aureus, P.aeruginosa and B 
cepacia complex are the most important bacteria in CF lung 
infections; however, other agents are emerging as S. malto-
philia, A. xylosoxidans, methicillin-resistant Staphylococcus 
aureus (MRSA) and nontuberculosis mycobacteria(20,23,24). 
In our study population, a similar pattern of microbiology 
distribution was observed, with prevalence of infections by P. 
aeruginosa and S. aureus, and the emergence of isolate cases of 
oxacilin-resistant S. aureus, Aspergillus spp, K. pneumonia, and 
other gram-negative bacteria, predominantly in the older age 
group of patients. Findings for the age group 6 to 11 are 
especially worrying as 64% of patients were already intermit-
tently or chronically colonized by P. aeruginosa at the initia-
tion of the therapy (T0), and this rate increased to 75% until 
the end of the follow-up period. In agreement with Bonestroo 
et al(25), we have not observed a positive effect of dornase alfa 
in reducing pulmonary colonization. However, our finding 
contrasts with results of a randomized study by Frederiksen 
et al(26), who demonstrated a significant reduction of airway 
colonization by gram-negative or gram-positive bacteria 
with dornase alfa, with the exception of P. aeruginosa. In this 
respect, we may speculate that our colonization results are 
not consistent with the clinical outcomes observed: during 
dornase alfa treatment there was a significant reduction in 
the number of hospitalizations, and emergency visits due to 
acute exacerbations in the younger group, in agreement 
to other studies(27). 
Treatment strategies for CF are known to be demand-
ing and have a complex scheme. Analysis of procedures 
performed in the daily routine, several times per day, 
including respiratory physical therapy, regular exercises, 
bronchodilators, oral and inhaled antibiotics, corticosteroids, 
dornase alfa, pancreatic enzymes and vitamins supplements, 
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besides home oxygen and insulin in selected cases, showed 
that patients and their families are constantly occupied in 
performing time-consuming routines and complex treatment 
schedules imposed by the disease, and therefore, have limited 
time for leisure and a poor quality of life(28) .            
A systematic review addressed the impact of dornase alfa 
compared to placebo or other mucolytics on morbidity and 
mortality, and found that the use of dornase alfa for a period 
over one month until two years was associated with an im-
provement in lung function(29). In our study, treatment with 
dornase alfa did not promote significant changes in a mean 
FEV
1
 after one year of use, as compared to baseline, in all age 
groups. It is known that an important aspect of CF evolution 
and prognosis is the rate of lung function decline, and slow-
ing this rate is crucial for long-term survival(13). Recently, an 
association between the use of dornase alfa for a period of two 
years and the reduction in the rate of FEV
1
 decline was observed 
in a large prospective observational study(13). In a placebo con-
trolled trial investigating the effects of long-term treatment 
with dornase alfa, it was shown that in young patients with CF, 
dornase alfa maintains lung function and reduces respiratory 
tract exacerbations. Considering that the progressive decline in 
lung function is a hallmark of CF, maintenance of lung func-
tion should be highlighted as an important achievement of the 
treatment(27). Similarly, our findings show a stabilization of lung 
function parameters at 6 and 12 months of dornase alfa, with 
no reductions in FEV
1
 over the one year period as it would be 
expected(30).Although not statistically significant, the absolute 
increase of 3% in the final mean of VEF
1
 in the younger group 
may be considered as a progress from a clinical perspective. 
This improvement or maintenance of VEF
1
 values confirms 
other findings showing the advantages of early introduction of 
dornase alfa for patients with mild disease (VEF
1
>80%) in the 
reduction of lung function decline rate(27). Delaying the decline 
in organ functions is one of the main goals of current treatments 
for CF, and initiation of dornase alfa early in the life is one of 
the identified factors associated with slower rate of decline in 
lung function(31). 
The importance of this publication resides on the fact 
that it was mostly prospective, following a standardized 
documentation used in all 16 CF centers, with a significant 
number of patients. Although information collected at T0 
was based on retrospective data, it was important to obtain 
the standard patterns of care and clinical characteristics of 
this population before treatment. Obtaining baseline data 
of a population to allow future comparisons is one of the 
elements that contribute to the good quality of research(18,32). 
However, an extended duration of the study, a wide spread of 
CF Centers across Brazil and CF patient personal problems 
had contributed to less than  ideal  register of collecting data, 
with missing data in all age groups, that was considered a 
limitation of the study.   
The lack of a control group not treated with dornase 
alfa and the heterogeneity of some clinical procedures 
adopted in the participating centers are also limitations 
of this study. The lack of a comparison group, not treated 
with dornase alfa, is a limitation that impairs a complete 
investigation about the benefits of the drug in CF patients. 
In view of the current recommendations regarding the use 
of dornase alfa, it was decided not to have a control group, 
as the use of placebo or another mucolytic drug would 
be ethically questionable(5,33). Nevertheless, in our study, 
subjects served as their own controls as clinical informa-
tion of the last 6 months prior to the study entry were 
rescued for each patient. Regarding variations in clinical 
management of the various centers, regular updating and 
contact between researchers have minimized differences in 
basic care approaches and monitoring of patients. Further 
multicenter research will be welcomed to clarify many 
clinical aspects and outcomes of CF patients without the 
limitations imposed by this study.
In summary, we have observed that CF patients have 
significant disease morbidity despite all routine therapies 
that they receive in CF centers. Dornase alfa promotes 
stabilization of lung function parameters, including FEV
1
, 
in patients aged 6–11 and ³14 years, and exerts a favorable 
impact on the clinical profile of CF patients irrespective 
of the age. 
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